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Abstract
Background: The combination of dendritic cells (DCs) and cytokine-induced killer cells (CIKs) can induce the
anti-tumor immune response and radiotherapy may promote the activity. We aimed to explore the feasibility of
DCs/CIKs combined with thoracic radiotherapy (TRT) for patients with locally advanced or metastatic non-small-cell
lung cancer (NSCLC).
Method: In this study, patients with unresectable stage III/IV NSCLC and an Eastern Cooperative Oncology Group
performance status (ECOG PS) of 0–2 and previously receiving two or more cycles of platinum-based doublet
chemotherapy without disease progression received TRT plus DCs/CIKs or TRT alone until disease progression or
unacceptable toxicity. The primary endpoint was median progression-free survival (mPFS). In treatment group,
patients received four-cycle autologous DCs/CIKs infusion starting from the 6th fraction of irradiation.
Results: From Jan 13, 2012 to June 30, 2014, 82 patients were enrolled, with 21 patients in treatment group and
61 in control group. The mPFS in treatment group was longer than that in control group (330 days vs 233 days,
hazard ratio 0.51, 95 % CI 0.27–1.0, P < 0.05), and the objective response rate (ORR) of treatment group (47.6 %)
was significantly higher that of control group (24.6 %, P < 0.05). There was no significant difference in disease
control rate (DCR) and median overall survival (mOS) between two groups (P > 0.05). The side effects in treatment
group were mild and there was no treatment-related deaths.
Conclusion: The combination of DCs/CIKs with TRT could be a feasible regimen in treating locally advanced or
metastatic NSCLC patients. Further investigation of the regimen is warranted.
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Introduction
Lung cancer is the most commonly diagnosed cancer
worldwide (1.8 million, 13.0 % of the total), and also a
leading cause of cancer death (1.6 million, 19.4 % of the
total) [1]. Patients with non-small cell lung cancer
(NSCLC) account for more than 80 % of those with lung
cancers [2]. Although much progress has been made in
the last decade in lung cancer treatment, the overall 5-
year survival rate is still less than 20 % [3]. More efforts
are needed to improve the prognosis of NSCLC patients.
Thoracic radiotherapy (TRT) plays an irreplaceable
role in treating NSCLC patients, especially those with
medically inoperable or locally advanced unresectable
disease [4]. Accumulating evidences show that TRT may
stimulate the anti-tumor immune response [5–8]. Tumor
cells killed by irradiation of more than a total dose of
10Gy [9] release tumor antigens that induce numerous
immune modulatory molecules [10, 11] and promote
tumor-specific effector CD8+ T cells via dendritic cell
(DC) activation [7]. DCs are the major antigen-presenting
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cells, and play a central role in regulating and activating
anti-tumor immune response [12, 13]. CIKs which express
both T cell marker CD3+ and NK cell marker CD56+ dis-
play a strong anti-tumor activity [14]. DCs/CIKs cytother-
apy is clinically efficient and can be well tolerated in
tumor patients [15, 16]. Based on the hypothesis that
DCs/CIKs combined with TRT could benefit the NSCLC
patients, we therefore sponsored a phase II clinical trial
from January 2012 to June 2014, and explored the efficacy,
safety and immunologic effects of DCs/CIKs combined
with TRT in patients with NSCLC.
Patients and methods
Study design and patients
This prospective single-center, open-label, phase II study
was conducted at the Cancer Institute of PLA, Xinqiao
Hospital, Third Military Medical University, Chongqing,
China. This trial was registered at Chinese Clinical Trial
Registry (ChiCTR-TRC-12002369, http://www.chictr.org.cn)
and approved by the Ethics Committee of General Lo-
gistics Department of PLA, China.
Eligible patients were histologically or cytologically
(not including sputum cytology) diagnosed with unre-
sectable stage III or IV advanced NSCLC (according to
the 7th edition of the General Rule for Clinical and
Pathological Record of Lung Cancer) [17]. All enrolled
stage III patients were reluctant to receive or were not
suitable for concurrent chemoradiotherapy or radical
radiotherapy because of certain conditions, such as huge
primary tumors, potential risk of heart failure, respira-
tory dysfunction and previous chemotherapy in other
medical center, etc. Other inclusion criteria included an
age of 18 years or older at the time of signing consent
form; a life expectancy of 3 months or longer at the
registration; an Eastern Cooperative Oncology Group
performance status (ECOG PS) of 0–2; adequate func-
tion of the liver, kidney, heart and hematopoietic system;
two or more cycles of previous platinum-based doublet
chemotherapy without disease progression. No previous
DCs/CIKs cytotherapy or TRT was allowed. One or
more measurable lesions are necessary for therapeutic
evaluation based on Response Evaluation Criteria in
Solid Tumors (RECIST 1.1) [18]. All study participants
provided “written informed consent”. Major exclusion
criteria included an acute infection; any autoimmune
disease; a history of severe allergic reaction; HIV-positivity;
pregnancy or nursing.
A block randomization was designed at the beginning,
with estimated median progression-free survival (mPFS)
of 6 months in control group, one-sided significance
level of 0.1 and a power of 0.7. The target sample size
was set at 120 patients (1:1), and dropouts were allowed.
However, it would take a very long period of time to
finish the enrollment because of the high medical cost
of DCs/CIKs cytotherapy, which was excluded from
medical insurance in China. Therefore, from Jan 13, 2012
to June 30, 2014, enrolled patients were assigned to con-
trol group and treatment group at their will instead of
randomization. Patients in control group received TRT
alone, while the patients in treatment group received TRT
in combination with DCs/CIKs cytotherapy that started
from the 6th fraction of irradiation (Fig. 1a). The primary
endpoint for this clinical trial was mPFS, and the second-
ary endpoints were objective response rate (ORR), disease
control rate (DCR), median overall survival (mOS), PS
change and side effects. Immunologic effects were to be
explored. After TRT, enrolled patients would continue
chemotherapy to reach a standard of 6 cycles in total.
Preparation of autologous DCs and CIKs
Autologous DCs and CIKs were prepared following the
previous studies [19–21] (Fig. 1b). Briefly, peripheral
blood mononuclear cells (PBMCs) were isolated by
Ficoll-Hypaque gradient density centrifugation, and then
cultured in X-VIVO medium for 2 h. The adherent cells
were collected for preparing DCs in X-VIVO medium
containing granulocyte macrophage colony-stimulating
factor (GM-CSF) and interleukin-4 (IL-4). Five days later,
tumor necrosis factor-α (TNF-α) and MUC-1 peptide
(SAPDTRPAPGSTAPPAHGVT) (GL Biochem, Shanghai,
China) were added into DCs culture for another 2 days.
For preparing CIKs, non-adherent cells were cultured in
X-VIVO medium containing interferon γ (IFN-γ), CD3
monoclonal antibody, and interleukin-2 (IL-2) for 10 days.
The immune phenotype markers CD80, CD83, CD86, and
HLA-DR for DCs and CD3, CD56 for CIKs were analyzed
by flow cytometry. Contamination of bacteria, fungi and
endotoxin in all the cultured samples were detected dur-
ing the course of cell culture.
DCs/CIKs cytotherapy
At the beginning of the study (day 0), we collected PBMCs
from the patients for culturing DCs and CIKs respectively
in vitro. Subsequently, over 1 × 107 DCs were injected sub-
cutaneously in the lymph node-rich regions (bilateral axil-
lary or inguinal region) on days 7, 14, 21, and 28. Over
1 × 109 CIKs in 100 mL of of normal saline (NS) (0.9 %)
were infused intravenously once a day for 4 consecutive
days from day 11 to day 14 (Fig. 1a).
TRT regimens
The interval between chemotherapy and enrollment was
no less than 14 days. TRT including three-dimensional
conformal radiotherapy (3D-CRT) or intensity-modulated
radiotherapy (IMRT) was adopted according to NCCN
guideline for patients with advanced NSCLC. Contour
delineation and radiotherapy plan was designed and
confirmed by the professional radiation oncologist. TRT
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was delivered at 2 Gy per fraction, 5 fractions per week, to
a total dose of 60–66 Gy at planning gross tumor volume
(pGTV) in 6–7 weeks. All plans were performed with
the support of four-dimensional chest CT. The normal
lungs received a limited radiation according to NCCN
guidelines.
Assessment of clinical outcomes
According to RECIST 1.1 [18], the treatment efficacy
was classified as complete response (CR), partial response
(PR), stable disease (SD), and progression disease (PD).
The ORR was defined as the percentage of patients with
CR or PR, and DCR was defined as the percentage of pa-
tients with CR, or PR, or SD. mPFS was defined as the
median time scale from enrollment to disease progression,
while mOS was the median time scale from first treatment
to death. The follow-up was performed at the 1st and 3rd
month after TRT, and then every 3 months for the first
year, and every 6 months thereafter. Routine follow-up
assessments included physical examinations, vital signs,
computed tomographic scans (CT), and laboratory tests.
Assessment of immunologic effects
Blood-drawing from participants was performed on day
0 and within a week after TRT (Fig. 1a). Cytokines (IL-2,
IFN-γ) in serum were detected by enzyme-linked im-
munosorbent assay (ELISA) (R&D Systems, MN, USA)
following the manufacturer’s instruction. For assay of T cell
populations and NK cells, 100 μL of EDTA anticoagulant
blood samples were stained with corresponding antibodies
(BD Bioscience), namely, anti-CD3+, CD4+ and CD8+ for T
cells, anti-CD3+ and CD56+ for NK cells, in darkness for
20 min. Then, erythrocyte lysis buffer was added. After be-
ing vortexed for 15 s and incubated at room temperature
for 5 min, the samples were centrifuged to remove the
supernatant and washed with PBS. After being re-
suspended with staining buffer, the samples were analyzed
on the BD Aria flow cytometer (BD Bioscience).
PS and side effects
Adverse effects, such as insomnia, anorexia, fever, skin
rash, and joint pain, were monitored and were observed
once a week during the therapy and once a month during
Fig. 1 Study design and workflow. a The study design of treatment group and control group in clinical trial. b The schematic diagram of
collection and infusion of autologous DCs/CIKs cells
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the follow-up. PS was evaluated on day 0 of the study and
within a week after the TRT.
Statistical analysis
The measurement data were expressed as mean ± stand-
ard deviation x  sð Þ and analyzed with the independent
Student t test. The enumeration data were analyzed
using χ2 test. Kaplan-Meier curves with the log-rank test
were used to estimate mPFS and mOS. Hazard ratio
(HR) and 95 % CI were also calculated by Cox propor-




From January 13, 2012 to June 30, 2014, a total of 82 pa-
tients with locally advanced or metastatic NSCLC were
enrolled, with 21 patients in treatment group and 61 in
control group (Fig. 2). Clinicopathological characteristics
such as age, gender, PS, clinical stage of tumor, previous
systemic chemotherapy, pathological type and PS in
treatment and control groups were analyzed. None of
them showed significant differences (Table 1, P > 0.05),
which meant a nearly identical baseline between the two
groups.
Clinical outcomes
The median follow-up time in treatment and control
groups was 339 and 393 days, respectively. 0 CR, 10 PR,
9 SD and 2 PD were found in treatment group, and 0
CR, 15 PR, 39 SD and 7 PD were found in control
group. ORR in treatment group is higher than that in
control group (47.6 % vs. 24.6 %, P = 0.04) (Fig. 3). How-
ever, no obvious difference in DCR was observed between
the two groups (90.5 % vs. 88.5 %, P = 0.767).
As for long-term evaluation, the mPFS of treatment
group (330 days) was significantly longer than that of
control group (233 days) (HR 0.51, 95 % CI 0.27–1.0,
P = 0.0483). However, there was no significant differ-
ence in mOS between treatment group (400 days) and
control group (460 days) (HR 0.83, 95 % CI 0.41–1.69,
P = 0.606) (Fig. 4).
Immunologic response
Among the 61 patients in control group, complete im-
munologic results were obtained in only 20 cases before
and after TRT. There was a lack of some medical materials
in the rest patients because of their refusal to draw blood
and the delayed follow-up, and some other reasons. These
20 cases were analyzed by assessing the baseline (Table 2)
and immunologic effects. The results of cytokines (IL-2,
Fig. 2 The profile of clinical trial








Mean (Range) 56.6 (32–74) 56.4 (31–74) 0.95
Gender
Male 19 (90.5 %) 53 (86.9 %)
Female 2 (9.5 %) 8 (13.1 %) 0.73
Clinical stage
III 10 (47.6 %) 37 (60.7 %)
IV 11 (52.4 %) 24 (39.3 %) 0.30
Tumor histology
Adenocarcinoma 8 (38.1 %) 26 (42.6 %)
Squamous carcinoma 13 (61.9 %) 35 (57.4 %) 0.72
Cycles of previous chemotherapy 2.9 ± 0.7 3.1 ± 0.8 0.53
PS score 0.4 ± 0.6 0.6 ± 0.7 0.35
Fig. 3 The short-term clinical effects. *ORR is significantly higher in
treatment group (P < 0.05)
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IFN-γ), T cell populations and NK cells were analyzed.
The serum levels of IL-2 and IFN-γ did not differ sig-
nificantly between the two groups both before and after
the TRT (Table 3, P > 0.05). Moreover, there were no
obvious changes in the percentage of CD3+, CD3+CD4+,
CD3+CD8+, CD4+/CD8+ T cell ratio and CD3−CD56+ NK
cells before and after TRT in treatment group (P > 0.05).
However, it should be noted that there was a decrease in
CD4+/CD8+ T cell ratio after TRT in control group, with a
P value close to 0.05 (Table 3, P = 0.08).
PS and side effects
At the beginning of the study, the PS in treatment and
control groups was 0.4 ± 0.6 and 0.6 ± 0.7, respectively
(Table 1). At the end of TRT, the PS in treatment and
control groups were 0.9 ± 0.8 and 1.4 ± 0.6, respectively.
Little PS increase was found in treatment group after
TRT (0.48 ± 0.7). However, obvious PS increase was re-
corded in control group (0.9 ± 0.7). The PS increase in
treatment group was significantly lower than that in
control group (P = 0.018, Table 4).
Side effects were assessed in all the 21 cases in treat-
ment group, and 59 of 61 cases in control group, with
incomplete follow-up information in 2 cases. The func-
tions of the liver, kidney and heart of all the participants
remained normal at the end of the TRT treatment. The
most commen side effects were fever, anorexia, nausea,
vomiting, myelosuppression, and radiation pneumonitis
(Table 3). Most of them were at level I ~ II, except radi-
ation pneumonitis. Radiation pneumonitis with grade 3
was observed in 3 patients in treatment group (14.3 %),
and 9 patients in control group (15.3 %). All patients re-
covered after suitable treatment within 2 months. There
were no cases with grade 4 radiation pneumonitis and
treatment-related deaths.
Discussion
Cancer cytotherapy is a novel therapeutic approach with
great potential [22–24]. Since the report of the first
DCs-based cancer vaccine clinical trial in 1995 [25], a
lot of trials have been designed and conducted [26, 27].
In 2010, Food and Drug Administration (FDA) approved
the first DCs-based vaccine Provenge for the treatment
of advanced prostate cancer [23, 28]. Additionally, the
cytotoxic and regulatory anti-tumor effects of CIKs are
also attractive and promising. The combination of DCs
with CIKs is a viable adoptive cytotherapy with a strong
anti-tumor effect [29, 30]. It was shown that irradiation
enhanced MHC I expression, and changed the tumor
microenvironment to boost greater infiltration of immune-
effector cells [31–33]. Tumor cells killed by irradiation
released tumor antigens which were presented by ectopic
DCs [10]. Both preclinical and clinical researches proved
that radiotherapy combined with cytotherapy elicited
greater anti-tumor response [34, 35].
As for the clinical outcomes of our study, a longer
mPFS was observed in treatment group than in control
group (330 days vs 233 days, P < 0.05), and ORR was
higher in treatment group (47.6 % vs 24.6 %, P < 0.05).
Fig. 4 Kaplan-Meier curves of mPFS and mOS. a. Compared with control group, mPFS in treatment group is significantly longer (P < 0.05). b. No
significant mOS difference between treatment group and control group (P > 0.05)









Mean (Range) 56.6 (32–74) 54.3 (39–68) 0.48
Gender
Male 19 (90.5 %) 17 (85 %)
Female 2 (9.5 %) 3 (15 %) 0.66
Clinical stage
III 10 (47.6 %) 10 (50 %)
IV 11 (52.4 %) 10 (50 %) 0.88
Tumor histology
Adenocarcinoma 8 (38.1 %) 10 (50 %)
Squamous carcinoma 13 (61.9 %) 10 (50 %) 0.44
Cycles of previous chemotherapy 2.9 ± 0.7 2.4 ± 0.5 0.06
PS score 0.4 ± 0.6 0.5 ± 0.6 0.91
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Although there was no significant difference in DCR and
mOS between the two groups (P > 0.05), the positive re-
sults in mPFS and ORR were still encouraging. Thus,
patients treated with DCs/CIKs combined with TRT
had a better clinical benefit. In the present study, we
started DCs/CIKs cytotherapy from the 6th fraction of
TRT to release enough tumor antigens. Our results val-
idate the hypothesis that tumor antigens released by
TRT could enhance tumor-specific killing via ectopic
DCs/CIKs infusion.
For safety analysis, during the combination therapy of
DCs/CIKs and TRT, a majority of side effects were mild,
tolerant and similar to TRT alone. No new safety signals
were identified, and no treatment-related deaths occurred.
In addition, we found a significant PS increase after TRT
in control group (P < 0.05). Nevertheless, there was a
minor PS increase in treatment group (P > 0.05). It sug-
gests that combined cytotherapy improves the PS for
advanced patients receiving TRT. Thus, DCs/CIKs in
combination with TRT shows a good safety profile.
Cancer patients often suffer from immune deficiency,
including a decrease in CD4+/CD8+ T cell ratio, especially
during a long period of systemic chemotherapy [36]. In
the present study, we found that there was a tendency of a
decrease in CD4+/CD8+ T cell ratio after TRT in control
group (P = 0.08) instead of in treatment group (Table 2).
Thus, a reasonable explanation could be that radical TRT
with conventional fractionation causes immune suppres-
sion in control group, and DCs/CIKs cytotherapy partially
rescues immune suppression induced by TRT in treat-
ment group.
Meanwhile, the current study detected other cytokines,
such as IL-2 and IFN-γ in peripheral blood, which were
supposed to play critical roles in specific immunological
effects and promoting innate and adaptive immune re-
sponses [37]. The serum levels of IL-2 and IFN-γ did not
change significantly after TRT in both groups (P > 0.05).
Since the immune response is very complex in DC/CIK
combined with TRT, further research is needed to reveal
cytokine activity in the future.
Given that irradiation-mediated immune responses
alter the tumor micro-environment, more and more re-
searches have explored that local radiation combined
with CTLA-4 blockade [38] or PD-L1 blockade [39]
could promote anti-tumor immunity. Our results also
suggest that the combination of cytotherapy with TRT is
a novel feasible application. It shows better clinical benefit,
a good tolerance, minor PS change, and promotes the
Table 3 Immunology response of patients x  sð Þ
Group CD3+(%) CD3+CD4+(%) CD3+CD8+(%) CD4+/CD8+ CD3−CD56+(%) IL-2 (ng/L) IFN-r (pg/mL)
Treatment group
Pre-treatment 62.16 ± 13.62 33.64 ± 10.05 25.86 ± 10.30 1.55 ± 0.88 17.83 ± 9.04 330.42 ± 79.25 575.85 ± 179.85
Post-treatment 66.34 ± 13.65 34.63 ± 13.28 29.73 ± 11.14 1.45 ± 0.97 17.31 ± 9.50 330.94 ± 66.12 567.12 ± 151.64
P value 0.3 0.716 0.119 0.684 0.806 0.979 0.831
Control group
Pre-treatment 68.70 ± 15.48 39.48 ± 12.76 27.30 ± 8.79 1.57 ± 0.67 10.25 ± 6.12 358.37 ± 49.00 491.19 ± 60.00
Post-treatment 70.43 ± 19.67 33.6471 ± 18.02 33.65 ± 17.19 1.27 ± 0.96 8.52 ± 6.52 376.09 ± 44.44 507.32 ± 59.87
P value 0.705 0.051 0.077 0.08 0.378 0.186 0.481
Table 4 PS and side effects
Characteristics Treatment group (n = 21) Control group (n = 59)
Grade 1–2 Grade 3 Grade 4 Grade 1–2 Grade 3 Grade 4
Fever 5 (23.8 %) 0 0 13 (22.0 %) 0 0
Anorexia 3 (14.3 %) 0 0 6 (10.2 %) 0 0
Allergy 1 (4.8 %) 0 0 0 0 0
Nausea, vomiting 3 (14.3 %) 0 0 9 (15.3 %) 0 0
Heart function 0 0 0 0 0 0
Liver function 0 0 0 0 0 0
Renal function 0 0 0 0 0 0
Myelosuppression 2 (9.5 %) 0 0 8 (13.6 %) 0 0
Radiation pneumonitis 4 (19.0 %) 3(14.3 %) 0 11 (18.6 %) 9(15.3 %) 0
PS change after TRT 0.48 ± 0.7* 0.9 ± 0.7
*PS change is significantly better than control group (P < 0.05)
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immunity to some extent. However, further studies are
needed with larger sample sizes. In addition, due to the
lack of randomization and thus possible bias (e.g. more
wealth, better education, better supportive care in treat-
ment group), activity needs to be further evaluated in a
properly designed randomized trial. Standardized treat-
ment schedule and detailed mechanism of DCs/CIKs
combined with TRT should be elucidated in the ongoing
research.
Conclusions
Our study confirms the efficiency and safety of the com-
bination of DCs/CIKs cytotherapy with TRT in advanced
NSCLC. Indeed, this novel strategy enhances immunity,
improves ORR, prolongs mPFS, and barely changes PS,
with no severe treatment-related side effects. It is therefore
a feasible regimen for patients with advanced NSCLC.
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